论坛 › 海南 › 中国最新癌症报告出炉！肺癌、肝癌、胃癌成三大难治癌症，有哪些新药新疗法值得关注！

b1gc8v 发表于 2024-6-13 20:52:16

中国最新癌症报告出炉！肺癌、肝癌、胃癌成三大难治癌症，有哪些新药新疗法值得关注！

<img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIvpSsy2iceFHnXfxg0j2MxhJnxLN6t5MJm8CDq9YScctialnUdia3m3a1btoW5TicZia60C2vNFFVuicaA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;"><span style="color: black;">关注<span style="color: black;">没</span>癌家园·<span style="color: black;">咱们</span><span style="color: black;">一块</span>战胜癌症</span></strong><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIvpSsy2iceFHnXfxg0j2MxhLbOyyxicfn00XZ0EjqVZLm4ybnGe9p9XZeACg6EIARhj42K6iasKxkibQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/5klfMQpnRNhiatJfBcDy6Gic7MvF28kmiaicXcZtytt7Ca4SUdTvjbB6enW5dLjHWBQuRXpUNENkxah9g819icAxOoA/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">伴同</span>着老龄化的加剧，世界范围内癌症<span style="color: black;">病人</span>的数据<span style="color: black;">起始</span><span style="color: black;">持续</span><span style="color: black;">增多</span>。<span style="color: black;">做为</span>世界上的人口大国，中国的癌症数据并不容<span style="color: black;">阳光</span>，不论是新发人数还是死亡人数，中国都位居<span style="color: black;">全世界</span><span style="color: black;">第1</span>。</span><span style="color: black;"><span style="color: black;">按照</span>世界卫生组织国际癌症<span style="color: black;">科研</span><span style="color: black;">公司</span>（IARC）最新<span style="color: black;">颁布</span>的《2020年<span style="color: black;">全世界</span>最新癌症<span style="color: black;">包袱</span>数据》<span style="color: black;">表示</span>：2020年<span style="color: black;">全世界</span>新发癌症病例1929万例，其中中国新发癌症457万人，占<span style="color: black;">全世界</span>23.7%，高居<span style="color: black;">全世界</span><span style="color: black;">第1</span>！<span style="color: black;">咱们</span>身边有越来越多的人<span style="color: black;">病患</span>癌症！</span><span style="color: black;"><span style="color: black;">那样</span>，到底我国最新癌症数据是<span style="color: black;">怎样</span>的呢？到底<span style="color: black;">那些</span>癌症高发<span style="color: black;">那些</span>癌症死亡率高？就在2022年2月27日，国家癌症中心<span style="color: black;">颁布</span>了<span style="color: black;">大众</span>翘首以盼的中国最新癌症报告。<span style="color: black;">因为</span>国家癌症数据统计<span style="color: black;">一般</span>延迟3~5年，<span style="color: black;">日前</span>的最新数据统计的是2016年的癌症发病率及死亡率。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIvpSsy2iceFHnXfxg0j2MxhIb4OnN4Hfh7Kgujoia3icN8vckIQmAV3XubFYVicH9l5rV1enj4IBojyA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;"><strong style="color: blue;">三大高发癌症：肺癌、结直肠癌、胃癌</strong></span>SUMMARY<span style="color: black;">我国2016年估计新发癌症病例近406.4万，其中男性223.4万，女性183.0万；</span><span style="color: black;"><strong style="color: blue;">位列前三位的高发癌症分别是</strong></span><span style="color: black;"><strong style="color: blue;">肺癌（82.8万）、结直肠癌（40.8万）、胃癌（39.7万）。</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">男性：</span></strong></span><strong style="color: blue;"><span style="color: black;">肺癌是最<span style="color: black;">平常</span>的癌症</span></strong><span style="color: black;">，约占男性所有新发癌症的24.6%（549,800 例），</span><span style="color: black;"><strong style="color: blue;">其次是肝癌、胃癌、结直肠癌和食管癌</strong></span><strong style="color: blue;"><span style="color: black;">。</span></strong><span style="color: black;">这五种癌症约占男性新诊断癌症的68.83%。</span><strong style="color: blue;"><span style="color: black;">女性：</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">乳腺癌是最<span style="color: black;">平常</span>的癌症</span></strong></span><span style="color: black;">，占女性所有新发癌症的16.72%（30.6万），</span><span style="color: black;"><strong style="color: blue;">其次是肺癌、结直肠癌、甲状腺癌和胃癌。</strong></span><span style="color: black;">这五种癌症约占女性新诊断癌症的56.11%。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIKpKZibNTjKM80fuqNdjKdRcHSESf1KY1DXQj8ulibAMlCHkC7p3JN1swxsG9dLJYjqZicGz6dZOcjQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;"><strong style="color: blue;">三大死亡率最高癌症：肺癌、肝癌、胃癌</strong></span>SUMMARY<span style="color: black;">2016年，中国<span style="color: black;">大概</span>241.35万人死于癌症。肺癌是男女癌症死亡的最<span style="color: black;">平常</span><span style="color: black;">原由</span>。其中男性153.1万，女性88.3万；</span><span style="color: black;"><strong style="color: blue;">位列前三位的癌症分别是</strong></span><span style="color: black;"><strong style="color: blue;">肺癌（65.7万）、肝癌（33.6万）、胃癌（28.9万）。</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">男性：</span></strong></span><span style="color: black;"><strong style="color: blue;">肺癌是最<span style="color: black;">平常</span>的癌症死亡<span style="color: black;">原由</span></strong>，肺癌死亡人数约占所有癌症死亡人数的29.71%（45.47万人），<strong style="color: blue;">其次是肝癌、胃癌、食道癌和结直肠癌。</strong>这5类癌种约占男性癌症死亡总数的75.87%。</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">女性：</span></strong></span><span style="color: black;"><strong style="color: blue;">肺癌是最<span style="color: black;">平常</span>的癌症死亡<span style="color: black;">原由</span></strong><strong style="color: blue;">，</strong><strong style="color: blue;">其次是胃癌、肝癌、结直肠癌和乳腺癌。</strong>这5类癌种约占女性癌症死亡总数的 60.06%。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIKpKZibNTjKM80fuqNdjKdRw17Ktf0Vbs4qkib6db1gOmGToHMicMeD5Xwlt4Awa7Qqke05T7jUj0AQ/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;">看到<span style="color: black;">以上</span>数据，<span style="color: black;">博主</span>不由感叹，在男性和女性中，<strong style="color: blue;">死亡率最高的都是肺癌，真的不愧是“万癌之王”。</strong>而仅次于肺癌的<strong style="color: blue;">肝癌和胃癌</strong><span style="color: black;">亦</span>都是<span style="color: black;">欠好</span>惹的主儿。这两大难治性癌症<strong style="color: blue;">均属于消化系统肿瘤</strong>。<span style="color: black;">针对</span>消化系统肿瘤，<span style="color: black;">日前</span>最有效的手段是手术，<span style="color: black;">然则</span>一旦缺乏手术指征，就几乎<span style="color: black;">无</span><span style="color: black;">尤其</span>有效的治疗手段。<span style="color: black;">因此呢</span>，亟需<span style="color: black;">研发</span>新<span style="color: black;">药品</span>、新疗法来<span style="color: black;">处理</span>这几大难治性癌症！</span><span style="color: black;"><span style="color: black;">那样</span>，接下来<span style="color: black;">没</span>癌家园<span style="color: black;">博主</span>就分享些针对这三大难治性癌症的新<span style="color: black;">药品</span>、新疗法，以供各癌友参考。</span><span style="color: black;"><strong style="color: blue;">万癌之王——肺癌</strong></span><span style="color: black;"><span style="color: black;">日前</span>，</span><span style="color: black;"><strong style="color: blue;">我国有将近80%的肺癌<span style="color: black;">病人</span>在初诊时就已属中晚期，5年存活率约为4%。</strong></span><span style="color: black;">虽然<span style="color: black;">日前</span>肺癌尚<span style="color: black;">没</span>彻底治愈的可能，但随着越来越多的抗癌药、抗癌技术的<span style="color: black;">显现</span>，<span style="color: black;">一般</span><span style="color: black;">长时间</span>治疗<span style="color: black;">掌控</span>肿瘤<span style="color: black;">发展</span>，将不治之症变成“慢性病”已<span style="color: black;">作为</span>可能！</span><strong style="color: blue;"><span style="color: black;">据<span style="color: black;">没</span>癌家园的专家介绍道：</span></strong><span style="color: black;"><span style="color: black;">按照</span><span style="color: black;">病人</span>的基因突变，<span style="color: black;">大夫</span>决定用特定<span style="color: black;">药品</span>的靶向治疗在肺癌中<span style="color: black;">已然</span><span style="color: black;">作为</span>一种有效的治疗手段。截止到<span style="color: black;">日前</span>为止，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">已然</span>有阳性<span style="color: black;">道理</span>基因突变的肺癌<span style="color: black;">病人</span>，<span style="color: black;">已然</span>达到非小细胞肺癌<span style="color: black;">病人</span>总数的70%，</strong></span><span style="color: black;">这<span style="color: black;">寓意</span>着将有70%的非小细胞肺癌<span style="color: black;">病人</span><span style="color: black;">能够</span><span style="color: black;">经过</span>基因检测找到对应的靶向<span style="color: black;">药品</span>，从而延长<span style="color: black;">存活</span>期。</span><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span></strong><strong style="color: blue;"><span style="color: black;"><a style="color: black;">70%非小细胞肺癌有靶向药可用，利用基</a>因检测“中靶”有望<span style="color: black;">作为</span>“超长<span style="color: black;">存活</span>者”！</span></strong><strong style="color: blue;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/qXeGgWfP2VubibFenoyoRrJQQL5Eib10atfpZ9S89dpdfAUPONJNZEzV6BGlQAme9iaSVic2WEy4d2cPpBEMvDPMdg/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></a></strong><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIKpKZibNTjKM80fuqNdjKdR4JIzVILyRfKOicafibhDSiccEWL7YfCRJVA7AojDnfgmEd6KOypEvQwgw/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">国内外多癌种靶向药临床<span style="color: black;">科研</span>进行中！</span></strong></span></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">1</strong></span><span style="color: black;"><strong style="color: blue;">拉罗替尼</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">两年多<span style="color: black;">败兴</span>，拉罗替尼在<span style="color: black;">全世界</span>多个国家落地开花，而今年，<span style="color: black;">最终</span>传来了即将进入中国的好<span style="color: black;">信息</span>。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">今年5月20日，CDE官网<span style="color: black;">表示</span>，拜耳在国内递交硫酸 Larotrectinib 胶囊上市申请并获受理（受理号：JXHS2101015）。这<span style="color: black;">寓意</span>着，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">全世界</span>首款不区分肿瘤<span style="color: black;">源自</span>的泛癌种靶向药有望在国内<span style="color: black;">获准</span></strong></span><span style="color: black;">，相信在不远的将来，国内的癌症<span style="color: black;">病人</span>会迎来这款“治愈系”抗癌药。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span><span style="color: black;"><a style="color: black;">只要NTRK融合突变，拉罗替尼、恩曲替尼两大“不限癌种”靶向药点燃晚期癌症新<span style="color: black;">期盼</span>！</a></span></strong></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">2</strong></span><span style="color: black;"><strong style="color: blue;">恩曲替尼</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2019年8月，FDA加速<span style="color: black;">准许</span>了<span style="color: black;">全世界</span>第三款广谱“治愈系”抗癌药</span><strong style="color: blue;"><span style="color: black;">Entrectinib</span></strong><span style="color: black;">（Rozlytrek，</span><span style="color: black;"><strong style="color: blue;">恩曲替尼</strong></span><span style="color: black;">，RXDX-101）上市，</span><span style="color: black;"><strong style="color: blue;">用于治疗成人和儿童<span style="color: black;">病人</span>神经营养原肌球蛋白受体激酶（NTRK）融合阳性、初始治疗后局部晚期或转移性实体肿瘤<span style="color: black;">发展</span>或<span style="color: black;">没</span>标准治疗<span style="color: black;">方法</span>的实体瘤<span style="color: black;">病人</span>（横跨10种不同类型肿瘤），以及ROS1阳性非小细胞肺癌（NSCLC）<span style="color: black;">病人</span>。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</strong></span></span><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><a style="color: black;">全身肿瘤</a>缩小77%，脑转移消失，横扫NTRK/ROS1/ALK靶点的广谱抗癌药什么来头！</strong></span></span></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">3</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">二代新药：瑞波替尼</span></strong></p><span style="color: black;">在2019年6月举行的美国临床肿瘤学会年会（ASCO）上，一款横扫</span><span style="color: black;"><strong style="color: blue;">ALK/ROS1/NTRK三靶点的靶向新药Repotrectinib（瑞波替尼，TPX-0005）</strong></span><span style="color: black;">的数据惊艳四座。</span><span style="color: black;">Repotrectinib是美国Turning Point Therapeutics<span style="color: black;">机构</span><span style="color: black;">研发</span>了一种新一代口服多靶点靶向药，对ALK、ROS1和NTRK都有<span style="color: black;">控制</span><span style="color: black;">功效</span>，能够克服多种对其他TKI产生抗性的基因突变，杀死携带ROS1、NTRK和ALK阳性的实体瘤。</span><span style="color: black;">在2019年ASCO大会上，<span style="color: black;">科研</span>者<span style="color: black;">发布</span>了其他ROS1<span style="color: black;">控制</span>剂（TKI）与Repotrectinib治疗ROS1阳性非小细胞肺癌<span style="color: black;">病人</span>疗效的最新数据。</span><span style="color: black;">11例可<span style="color: black;">评定</span>的ROS1阳性NSCLC <span style="color: black;">病人</span>的总体缓解率为82％，令人兴奋的是，</span><span style="color: black;"><strong style="color: blue;">颅内反应率为100％，临床受益率为100％，超越<span style="color: black;">日前</span>所有的靶向药。</strong></span><span style="color: black;">有望<span style="color: black;">作为</span>超越上市明星<span style="color: black;">制品</span>Larotrectinib (拉罗替尼，LOXO-101)、Entrectinib (恩曲替尼, RXDX-101)的新一代广谱抗癌新星。</span><span style="color: black;">2021年，新一代广谱抗癌药TPX-0005（Repotrectinib，瑞波替尼）的最新数据在世界肺癌大会上亮相，<span style="color: black;">导致</span>了巨大的轰动，并且在癌友圈中刷屏！在TRIDENT-1的I/II期<span style="color: black;">科研</span>中，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">针对</span>特定突变的ROS1阳性<span style="color: black;">病人</span>，</strong></span><span style="color: black;"><strong style="color: blue;">客观缓解率达到了93%，</strong></span><span style="color: black;"><strong style="color: blue;">创下了新的最高纪录，</strong>并且超越了“治愈系”抗癌药恩曲替尼，或将<span style="color: black;">作为</span>下一个抗癌“传奇”！</span><strong style="color: blue;">04</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">创新药：Taletrectinib</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Taletrectinib（DS-6051b，国内代号AB-106）是一款由日本<span style="color: black;">第1</span>三共株式会社<span style="color: black;">开发</span>、我国葆元生物引进国内并<span style="color: black;">起始</span>进行Ⅱ期临床<span style="color: black;">实验</span>的创新<span style="color: black;">药品</span>。<span style="color: black;">这里</span>前美、日中心的Ⅰ期临床<span style="color: black;">实验</span>中，AB-106<span style="color: black;">已然</span>展现出了不错的<span style="color: black;">潜能</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在2021年9月25日，同济大学<span style="color: black;">附庸</span>上海市肺科医院周彩存教授在CSCO大会上分享了</span><span style="color: black;"><strong style="color: blue;">Taletrectinib（AB-106）</strong></span><span style="color: black;"><span style="color: black;">科研</span>的最新结果，即</span><strong style="color: blue;"><span style="color: black;">新一代强效ROS1/NTRK<span style="color: black;">控制</span>剂治疗ROS1阳性非小细胞肺癌</span></strong><span style="color: black;">II期<span style="color: black;">科研</span>（TRUST<span style="color: black;">科研</span>）初步<span style="color: black;">科研</span>结果，卓越的数据令在座各位专家感到振奋，期待这款<span style="color: black;">药品</span><span style="color: black;">早点</span>上市，为<span style="color: black;">病人</span>带了新的<span style="color: black;">选取</span>和<span style="color: black;">期盼</span>。</span></p><span style="color: black;"><span style="color: black;"><strong style="color: blue;">1.未接受ROS1 TKI治疗组疗效：</strong></span><span style="color: black;"><strong style="color: blue;">客观缓解率高达90.5%！</strong></span></span><span style="color: black;"><span style="color: black;"><strong style="color: blue;">2.克唑替尼治疗失败组疗效：</strong></span><span style="color: black;"><strong style="color: blue;">客观缓解率43.8%！</strong></span></span><span style="color: black;"><span style="color: black;"><strong style="color: blue;">3.入脑效果强劲！</strong></span><span style="color: black;"><strong style="color: blue;">客观缓解率高达83.3%！</strong></span></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span><span style="color: black;"><a style="color: black;">好的靶向抗癌药，就</a>得“上头”！<span style="color: black;">困惑</span>60%肺癌<span style="color: black;">病人</span>的脑转移的克星<span style="color: black;">最终</span>来了！</span></strong></p><strong style="color: blue;">05</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">广谱新药JMT-101</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2019年，</span><span style="color: black;"><strong style="color: blue;">我国自主<span style="color: black;">开发</span>的、专门针对EGFR ex20in<span style="color: black;">病人</span>的新药JMT-101<span style="color: black;">已然</span><span style="color: black;">得到</span><span style="color: black;">准许</span>投入临床<span style="color: black;">实验</span>！</strong></span><span style="color: black;">并且在2020年ASCO线上会议中，首次<span style="color: black;">颁布</span>了这款<span style="color: black;">药品</span>治疗晚期结直肠癌<span style="color: black;">病人</span>的<span style="color: black;">实验</span>结果，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率达到100%</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">，引起轰动。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">好<span style="color: black;">信息</span>是，<span style="color: black;">日前</span>JMT-101治疗多种实体瘤的II期临床<span style="color: black;">实验</span><span style="color: black;">已然</span><span style="color: black;">持续</span><span style="color: black;">起始</span>。其中，<span style="color: black;"><strong style="color: blue;">治疗非小细胞肺癌的II期<span style="color: black;">实验</span>正在招募<span style="color: black;">病人</span>，若想参加临床<span style="color: black;">实验</span>请咨询<span style="color: black;">没</span>癌家园医学部（400-626-9916）。</strong></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：<a style="color: black;">EGFR ex20ins临床<span style="color: black;">实验</span>招募：换掉<span style="color: black;">哪些</span>效果<span style="color: black;">不良</span>的<span style="color: black;">方法</span>吧</a></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><a style="color: black;">国药厚积薄发，多款自主<span style="color: black;">开发</span>抗癌新药</a>疗效喜人，肺癌开启<span style="color: black;">没</span>化疗时代！</span></strong></span></p><strong style="color: blue;">06</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">ADC<span style="color: black;">药品</span>ABBV-399</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Telisotuzumab Vedotin（Teliso-v，ABBV-399）为</span><span style="color: black;"><strong style="color: blue;">新型c-MET靶点抗体<span style="color: black;">药品</span>偶联物（ADC）</strong></span><span style="color: black;">，在c-MET过表达的非小细胞肺癌<span style="color: black;">病人</span>的治疗中，<span style="color: black;">拥有</span>非常出色的<span style="color: black;">潜能</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2021年的AACR年会上，ABBV-399公开了其Ⅱ期<span style="color: black;">科研</span>的结果，在c-MET过表达的非小细胞肺癌<span style="color: black;">病人</span>的治疗中，<span style="color: black;">拥有</span>非常出色的<span style="color: black;">潜能</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在EGFR阴性的非鳞状非小细胞肺癌<span style="color: black;">病人</span>中，ABBV-399治疗的整体缓解率为35.1%，中位缓解<span style="color: black;">连续</span>时间为6.9个月;其中，c-MET高表达<span style="color: black;">病人</span>的整体缓解率为53.8%，低表达<span style="color: black;">病人</span>为25.0%。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span><span style="color: black;">包含</span><strong style="color: blue;">伯瑞替尼、ABBV-399、特泊替尼、卡马替尼</strong></span><span style="color: black;">在内</span><span style="color: black;">的多款MET<span style="color: black;">控制</span>剂新药的临床<span style="color: black;">实验</span>均在招募国内<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">因为</span><span style="color: black;">药品</span>种类较多，且部分<span style="color: black;">药品</span>尚未公开名<span style="color: black;">叫作</span>及<span style="color: black;">详细</span>数据，<span style="color: black;">因此呢</span><span style="color: black;">大众</span><span style="color: black;">能够</span>联系</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</span></strong></span><span style="color: black;">进行咨询，<strong style="color: blue;">由专业医学顾问<span style="color: black;">指点</span><span style="color: black;">大众</span>进行<span style="color: black;">选取</span>。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span></strong><a style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">控制</span>MET突变又<span style="color: black;">有效</span>抗脑转！肺癌新靶向药卡马替尼、</span></strong></a><strong style="color: blue;">赛沃替尼、特泊替尼强势崛起！</strong></p><strong style="color: blue;">07</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">针对KRAS g12c突变国药D-1553</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">鉴于AMG510<span style="color: black;">刚才</span><span style="color: black;">获准</span>上市，国人还<span style="color: black;">处在</span>一药难求的迫切<span style="color: black;">周期</span>，Adagrasib（MRTX849）还<span style="color: black;">处在</span><span style="color: black;">开发</span><span style="color: black;">周期</span>，我国的药企<span style="color: black;">亦</span>加大了关于KRAS靶点的新药<span style="color: black;">开发</span>进程。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">好<span style="color: black;">信息</span>是，针对</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">KRAS g12c突变的各类实体瘤<span style="color: black;">病人</span></span></strong></span><span style="color: black;">，一款</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">国产新<span style="color: black;">药品</span>——D-1553</span></strong></span><span style="color: black;"><span style="color: black;">已然</span>正式<span style="color: black;">起始</span>招募<span style="color: black;">病人</span>了！<span style="color: black;">期盼</span>参加的<span style="color: black;">病人</span><span style="color: black;">能够</span>咨询</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</span></strong></span><span style="color: black;"><span style="color: black;">认识</span>该<span style="color: black;">实验</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><a style="color: black;">国内外多癌种靶向药临床招募中！热门靶点NTRK、EGFR、KRAS、MET等一网打尽！</a></span></strong></span></p><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/LghKSGmMJfIQ3qIIZQwEv9mjmibZdZqNpgTgnDoA5auPO3zezhZ4KJoVDjkNC89kxo5MAiaFAr0rnW9ppia5cVOAA/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></a><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIKpKZibNTjKM80fuqNdjKdR4JIzVILyRfKOicafibhDSiccEWL7YfCRJVA7AojDnfgmEd6KOypEvQwgw/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">新疗法新技术对肺癌发起总攻！</strong></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">1</strong></span><strong style="color: blue;">CAR-T细胞疗法</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">CAR-T疗法<span style="color: black;">便是</span>嵌合抗原受体T细胞免疫疗法，是一种治疗肿瘤的新型<span style="color: black;">精细</span>靶向疗法。</span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">经过</span>基因工程技术将T细胞激活，并装上定位导航<span style="color: black;">安装</span>CAR（肿瘤嵌合抗原受体），将T细胞这个普通“战士”改<span style="color: black;">导致</span></span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">“超级战士”</span></strong></span><strong style="color: blue;"><span style="color: black;">，即CAR-T细胞，</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">专门识别<span style="color: black;">身体</span>肿瘤细胞，并<span style="color: black;">有效</span>杀灭肿瘤细胞</span></strong></span><strong style="color: blue;"><span style="color: black;">，从而达到治疗恶性肿瘤的目的。</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">301医院在国内率先开展CAR-T疗法，成果显著。</span></strong></span><span style="color: black;">韩为东教授曾<span style="color: black;">报告</span>过利用EGFR为靶点的CAR-T治疗EGFR表达强阳性（EGFR表达超过50%）的晚期难治性的非小细胞肺癌<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，其中11例<span style="color: black;">病人</span>疗效可<span style="color: black;">评估</span>：</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">2例<span style="color: black;">病人</span>肿瘤<span style="color: black;">显著</span>缩小，5例<span style="color: black;">疾患</span>稳定。</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">图A中<span style="color: black;">病人</span>1在输注CAR-T细胞后，<span style="color: black;">经过</span>CT扫描<span style="color: black;">表示</span>其胸腔积液减少，转移性肺门淋巴结和胸膜结节轻度缩小（箭头）。</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">图B中CT图像<span style="color: black;">表示</span><span style="color: black;">病人</span>8的原发性肿瘤缩小（箭头）；</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">图C中CT<span style="color: black;">检测</span><span style="color: black;">发掘</span>CAR-T治疗后<span style="color: black;">病人</span>9的胸腔积液吸收和肺部病变<span style="color: black;">显著</span>消退。</span></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：<a style="color: black;">国人屡向非小细胞肺癌进军，CAR-T联手PD-1/L1，有效<span style="color: black;">控制</span>肿瘤生长</a></strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfLJLZJC1v3JTrkXrFO5GxHKQ0QvqwhL97lCVIwWt3PiaUZyufONZWHSFxJVb4iajQQP6nezLN4yImyA/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">2</strong></span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">肿瘤浸润淋巴细胞（TIL）治疗</p>
      </strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">TILs疗法，简单点讲<span style="color: black;">便是</span>将手术切除的肿瘤组织中的淋巴细胞分离纯化，挑选出其中能特异性抗癌的淋巴细胞，扩增活化后回输。这类疗法<span style="color: black;">持有</span>30<span style="color: black;">数年</span>的历史，</span><span style="color: black;"><strong style="color: blue;">最早用于恶性黑色素瘤，近年来在宫颈癌、肺癌等多种实体瘤中都给出了不俗的数据。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">这个疗法相当于直接从战场上拉回有战斗经验的老兵，经过一轮“政治审查”和业务能力“大比拼”，把内奸、叛徒<span style="color: black;">尽可能</span>剔除出去，留下战斗力最强的，<span style="color: black;">供给</span>补给，再重新送回战场继续战斗。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">这种免疫治疗<span style="color: black;">办法</span><span style="color: black;">触及</span>采用<span style="color: black;">病人</span><span style="color: black;">自己</span>的免疫细胞来成功地攻击癌细胞，</strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">首要</span>用于黑色素瘤或血癌，如淋巴瘤和白血病。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</strong><a style="color: black;"><strong style="color: blue;">病灶完全消失，数十亿免疫细胞回输<span style="color: black;">身体</span>，TILs疗法让晚期肺癌<span style="color: black;">病人</span>已<span style="color: black;">没</span>癌3年！</strong></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">晚期肺癌PD-1耐药后束手<span style="color: black;">没</span>策？TILs细胞疗法联合PD-1</strong></a><strong style="color: blue;">仍能完全缓解！</strong></p><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfKyEw5pbsf1zJa6GKbV7IFNLTL9NCkcmlqvAS6HGM890FAQUOdcVibGpdaF8xl9OM079S0MDh64FWg/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">TILs免疫疗法招募</strong></span><strong style="color: blue;"><span style="color: black;"><span style="color: black;">日前</span><span style="color: black;">没</span>癌家园有一款TILs免疫细胞临床<span style="color: black;">实验</span>正在招募中，<span style="color: black;">重点</span>治疗</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">恶性实体肿瘤（<span style="color: black;">包含</span><strong style="color: blue;"><span style="color: black;">肺癌、食管癌、卵巢癌、宫颈癌、乳腺癌</span></strong>）</span></strong></span><strong style="color: blue;"><span style="color: black;">等癌种。</span></strong><strong style="color: blue;"><span style="color: black;">若想参加请咨询<span style="color: black;">没</span>癌家园医学部</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">（400-626-9916）</span></strong></span><strong style="color: blue;"><span style="color: black;">，<span style="color: black;">仔细</span><span style="color: black;">评定</span>病情。</span></strong><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">3</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">质子治疗</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">质子疗法为肺癌<span style="color: black;">病人</span><span style="color: black;">供给</span>一种全新的非手术治疗<span style="color: black;">办法</span>，</span><span style="color: black;"><strong style="color: blue;">适用于各个<span style="color: black;">周期</span>的肺癌<span style="color: black;">病人</span>，</strong></span><span style="color: black;">与传统的高能x射线辐射（或光子）不同。<span style="color: black;">因为</span>质子疗法独特的特性，它<span style="color: black;">能够</span><span style="color: black;">供给</span>特定深度的辐射剂量<span style="color: black;">而后</span><span style="color: black;">忽然</span>停下，后方<span style="color: black;">再也不</span>有射线照射剂量。而X射线照射治疗，会<span style="color: black;">连续</span>穿透正常组织、器官（如肺，心脏，食道和脊髓），<span style="color: black;">引起</span><span style="color: black;">损害</span>和毒性。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">下面是<span style="color: black;">针对</span>同一个<span style="color: black;">病人</span>调强x射线放射治疗（IMRT）平面图（左）和质子治疗计划（右）的对比。颜色渐变程度<span style="color: black;">表率</span>不同辐射剂量，红色高剂量，黄色和绿色中等剂量，蓝色低剂量。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/CwkERAMhICw2emYrBiapNoibT2c5YrrUMoHSfRB5XfDOcFXNaGGVQJIFfPI7rfkSYgyfoG59l3y0jeXBDZkZ3bpQ/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">针对</span>这例<span style="color: black;">病人</span>，对比X线放疗，</span><span style="color: black;"><strong style="color: blue;">质子计划大幅度减少了肿瘤<span style="color: black;">周边</span>健康组织的辐射剂量，例如右肺、食道和心脏。</strong></span><span style="color: black;">对这些区域的低剂量将减少辐射诱发的肺炎、吞咽<span style="color: black;">病痛</span>，还有心脏病危险。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span><span style="color: black;"><a style="color: black;">拿中心型肺癌没办法？传统放疗行</a>不通？采用质子疗法准没错！</span></strong></p><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">难缠的“老大哥”——肝癌</span></strong></p><span style="color: black;">肝癌是最著名的“穷人癌”，<span style="color: black;">由于</span>它在发展中国家，尤其是中国高发。据统计，我国原发性肝癌的发病和死亡例数占比分别占<span style="color: black;">全世界</span>的54.6%和53.9%，毫不夸张地说，我国基本上以<span style="color: black;">全世界</span>20%的人口认领了超过50%的肝癌<span style="color: black;">病人</span>。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">像<span style="color: black;">大众</span>熟悉的香港演员吴孟达、沈殿霞，音乐才子赵英俊，内地演员傅彪，诗人汪国真等，都是被肝癌夺去了生命！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">我国每年死于肝癌的约34.4万人，占世界肝癌死亡人数的55％，每一分多钟就会有一人死于肝癌。相<span style="color: black;">针对</span>高死亡率，<span style="color: black;">初期</span>肝癌的<span style="color: black;">发掘</span>比例却非常低，</span><span style="color: black;"><strong style="color: blue;">9成以上一经<span style="color: black;">发掘</span>就<span style="color: black;">已经是</span>晚期，此时已失去了手术治疗的机会，致使5年<span style="color: black;">存活</span>率仅为12%，中晚期肝癌<span style="color: black;">病人</span>的5年<span style="color: black;">存活</span>率<span style="color: black;">更加是</span>低至3%。</strong></span></span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">细胞免疫疗法有望<span style="color: black;">作为</span>战胜肝癌杀手锏</span></strong></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">1</strong></span><strong style="color: blue;">CAR-T细胞疗法</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，随着</span><strong style="color: blue;"><span style="color: black;">阿基仑赛注射液、瑞基奥仑赛注射液</span></strong><span style="color: black;">前后在中国<span style="color: black;">获准</span>上市，<strong style="color: blue;"><span style="color: black;">西达基奥仑赛</span>被美国FDA<span style="color: black;">获准</span>上市，</strong>癌症治疗<span style="color: black;">行业</span>火速掀起一阵“CAR-T热”。<strong style="color: blue;"><span style="color: black;">当前应用CAR-T治疗肝癌的临床<span style="color: black;">实验</span>靶点<span style="color: black;">重点</span>是</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">GPC3（磷脂酰肌醇蛋白多糖3）</span></strong></span><strong style="color: blue;"><span style="color: black;">。</span></strong></span></p><span style="color: black;">
      <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2021年ASCO年会上我国医学<span style="color: black;">科研</span>者们首次<span style="color: black;">颁布</span>了靶向GPC3的CAR-T<span style="color: black;">药品</span>（Ori-CAR-001）治疗复发/难治性肝细胞癌的最新临床<span style="color: black;">科研</span>数据。该<span style="color: black;">科研</span>的初步数据<span style="color: black;">表示</span>，Ori-CAR-001在GPC3阳性复发/难治性<span style="color: black;">病人</span>中表现出良好安全性和有效性。</p>
    </span><span style="color: black;"><span style="color: black;">截止</span>2021年3月10日，共纳入11名接受细胞输注的复发受试者。</span><span style="color: black;"><strong style="color: blue;">所有受试者均<span style="color: black;">身患</span>晚期肝细胞癌，并且经过化疗、TACE（肝动脉化疗栓塞术）和靶向治疗均<span style="color: black;">没</span>效。</strong></span><span style="color: black;">9例可<span style="color: black;">评定</span>受试者中，<strong style="color: blue;">4例达到部分缓解 (PR)，3例达到<span style="color: black;">疾患</span>稳定 (SD)，2例<span style="color: black;">显现</span><span style="color: black;">疾患</span><span style="color: black;">发展</span> (PD)，</strong></span><span style="color: black;"><strong style="color: blue;">客观缓解率为44%，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率达到78%</strong></span><span style="color: black;"><strong style="color: blue;">。</strong></span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">典型病例</strong><span style="color: black;">国际知名杂志《Journal of Hematology &amp; Oncology》刊登了我国医学<span style="color: black;">科研</span>者们的一项成功改造CAR-T技术的临床<span style="color: black;">科研</span>，<span style="color: black;">科研</span>中提及的CAR-T<span style="color: black;">制品</span><span style="color: black;">选取</span>的靶点是</span><span style="color: black;"><strong style="color: blue;">glypican-3（GPC3，<span style="color: black;">重点</span>是肝癌）</strong></span>。<span style="color: black;"><strong style="color: blue;">其中</strong></span><span style="color: black;"><strong style="color: blue;">1例晚期肝癌<span style="color: black;">病人</span>接受了瘤内注射CAR-T治疗，治疗后肝脏病灶代谢基本消失。</strong></span><span style="color: black;">CAR-T细胞</span><span style="color: black;"><strong style="color: blue;">注射60天后</strong></span><span style="color: black;">，虽然2个肺部结节的尺寸<span style="color: black;">无</span><span style="color: black;">明显</span>的改变，但在</span><strong style="color: blue;"><span style="color: black;">第10天时肝脏肿瘤病变（1.2×1.3cm）<span style="color: black;">明显</span>收缩</span></strong><span style="color: black;">，</span><strong style="color: blue;"><span style="color: black;">注射GPC3-7×19 CAR-T细胞第32天后则完全消失。</span></strong><span style="color: black;"><span style="color: black;">病人</span><span style="color: black;">无</span>任何毒性<span style="color: black;">功效</span>，并且<span style="color: black;">按照</span> CT 上的标准实体瘤反应<span style="color: black;">评定</span>标准 (RECIST) 1.1 版进行了分期<span style="color: black;">评定</span>，<span style="color: black;">表示</span>部分缓解 (PR)。</span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">2</strong></span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">肿瘤浸润淋巴细胞（TIL）治疗</p>
      </strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">TILs疗法，简单点讲<span style="color: black;">便是</span>将手术切除的肿瘤组织中的淋巴细胞分离纯化，挑选出其中能特异性抗癌的淋巴细胞，扩增活化后回输。这类疗法<span style="color: black;">持有</span>30<span style="color: black;">数年</span>的历史，最早用于恶性黑色素瘤，近年来在宫颈癌、肺癌等多种实体瘤中都给出了不俗的数据。</span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">近期</span>，《临床外科杂志》在线<span style="color: black;">发布</span>了国内学者关于TILs疗法技术在晚期肝癌中的临床<span style="color: black;">实验</span>，并观测到良好的安全性与有效性。TILs是一种过继性细胞疗法，分为两类：<span style="color: black;">没</span>筛选型TILs和筛查型TILs。随着抗PD-1治疗对肿瘤免疫逃避机制的<span style="color: black;">控制</span>，以淋巴细胞为<span style="color: black;">表率</span>的肿瘤杀伤细胞可能对肿瘤发挥更佳的杀伤效应。</span><span style="color: black;"><strong style="color: blue;">TILs联合抗PD-1治疗理论上将会对肿瘤细胞发挥更有效地协同杀伤<span style="color: black;">功效</span>，这有望<span style="color: black;">作为</span>一种<span style="color: black;">拥有</span>重大治疗前景的新型免疫联合治疗模式。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在<span style="color: black;">日前</span>进行的4例临床<span style="color: black;">实验</span>中，</span><span style="color: black;"><strong style="color: blue;">3例晚期肝细胞癌和1例肝内胆管癌<span style="color: black;">病人</span>的TILs体外扩增和回输均<span style="color: black;">得到</span>成功</strong></span><span style="color: black;">，TILs的最高扩增量达到3.5×1010个细胞。在4例<span style="color: black;">病人</span>中，仅1例<span style="color: black;">病人</span><span style="color: black;">显现</span>I级不良反应，4例<span style="color: black;">病人</span>细胞注射前后均未<span style="color: black;">出现</span>III/IV级严重不良反应。</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">日前</span>这两例晚期肝癌<span style="color: black;">病人</span>随访时间<span style="color: black;">已然</span>超过1年。</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">这是<span style="color: black;">日前</span>国内外首次应用免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂联合过继性免疫疗法在晚期肝癌上观察到<span style="color: black;">明显</span>疗效。</span></strong></span><span style="color: black;"><span style="color: black;">科研</span><span style="color: black;">显示</span>，TILs体外扩增后回输联合抗PD-1单抗治疗可能<span style="color: black;">作为</span>一种治疗肝癌的新<span style="color: black;">办法</span>。</span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">若经济<span style="color: black;">前提</span><span style="color: black;">准许</span>且想咨询TILs细胞疗法可将病理报告及治疗经历、出院小结等资料提交至</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</strong></span><strong style="color: blue;"><span style="color: black;">，<span style="color: black;">仔细</span><span style="color: black;">评定</span>病情。</span></strong></p><strong style="color: blue;">0</strong><span style="color: black;"><strong style="color: blue;">3</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;">TCR-T细胞疗法</strong></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">CAR-T 细胞和TCR-T细胞都属于经基因工程技术改造的T细胞。</span><span style="color: black;"><strong style="color: blue;">相较于CAR-T疗法，TCR-T疗法在实体瘤治疗<span style="color: black;">行业</span>具备独特<span style="color: black;">优良</span>。</strong></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">TCR-T细胞疗法可识别细胞膜表面或细胞内<span style="color: black;">源自</span>的肿瘤特异性抗原，已从最<span style="color: black;">起始</span>的<span style="color: black;">基本</span>免疫<span style="color: black;">科研</span>走进临床应用，在实体瘤中<span style="color: black;">表示</span>出初步疗效，<span style="color: black;">作为</span><span style="color: black;">日前</span>最有可能在实体瘤<span style="color: black;">行业</span>中取得突破的T细胞免疫疗法！</span></p><span style="color: black;"><strong style="color: blue;">国内TCR-T细胞疗法<span style="color: black;">获准</span>临床，<span style="color: black;">作为</span>HBV<span style="color: black;">关联</span>肝细胞癌的潜在新疗法！</strong></span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，除了<span style="color: black;">全世界</span>TCR-T<span style="color: black;">处在</span>如火如荼的<span style="color: black;">开发</span>及临床验证<span style="color: black;">周期</span>，国内<span style="color: black;">亦</span>在<span style="color: black;">持续</span>突破创新。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2021年12月22日，CDE（<span style="color: black;">药物</span>审评中心）官网能够<span style="color: black;">查找</span>到“SCG101自体T细胞注射液”的临床申请，此<span style="color: black;">制品</span>是一款针对特定乙型肝炎病毒（HBV）表位的TCR-T细胞疗法，是治疗HBV<span style="color: black;">关联</span>肝细胞癌（HCC）的潜在新疗法。</span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">▲ <span style="color: black;">照片</span><span style="color: black;">源自</span>：CDE官网</span></strong></p><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">晚期肝癌迎来新曙光！TCR-T疗法让癌症<span style="color: black;">病人</span>完全缓解</p>
      </strong></span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">早在2020年国际肝病大会（ILC）上，一款基于T细胞的肝癌新型TCR-T疗法ADP-A2AFP<span style="color: black;">导致</span>了不小的轰动，<span style="color: black;">亦</span>让肝癌的新疗法有了新的突破。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">在纳入的<span style="color: black;">病人</span>中，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">有一名<span style="color: black;">病人</span>的癌细胞进程<span style="color: black;">显现</span>了完全缓解（CR）的表现，其余参与者的甲胎蛋白（AFP）<span style="color: black;">亦</span>都<span style="color: black;">显现</span>了不同程度的下降，</span></strong></span><span style="color: black;">这<span style="color: black;">寓意</span>着<span style="color: black;">实验</span>取得了<span style="color: black;">发展</span>，<span style="color: black;">亦</span>说明该疗法针对晚期肝癌的治疗是有效果的。</span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：<a style="color: black;">重磅！<span style="color: black;">全世界</span>首款TCR-T细胞</a>疗法<span style="color: black;">获准</span>上市！实体瘤细胞疗法有望迎来突破！</span></strong></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园TCR-T疗法招募</strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">那样</span>到底有<span style="color: black;">无</span>机会尝试TCR-T疗法呢？</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">博主</span>这就带来了一个好<span style="color: black;">信息</span>，</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">日前</span>正有一项<span style="color: black;">开发</span>的TCR-T疗法在招募肝癌<span style="color: black;">病人</span>开展临床<span style="color: black;">实验</span>，</strong></span><span style="color: black;"><strong style="color: blue;">想要参加的<span style="color: black;">病人</span><span style="color: black;">能够</span>咨询</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">认识</span><span style="color: black;">仔细</span>入排标准。</strong></span><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">没</span>声的杀手——胃癌</strong></p><span style="color: black;">我国是胃癌高发国家，据全国肿瘤登记中心最新数据估计，位居同期恶性肿瘤发病第2位。胃癌整体预后较差，5年<span style="color: black;">存活</span>率仅10%～30%，晚期胃癌<span style="color: black;">病人</span>5年<span style="color: black;">存活</span>率<span style="color: black;">小于</span>10%，晚期胃癌一线治疗的<span style="color: black;">科研</span>结果<span style="color: black;">表示</span>，总<span style="color: black;">存活</span>期（OS）在<span style="color: black;">持续</span>延长，但中位<span style="color: black;">存活</span>期仍在12个月<span style="color: black;">上下</span>。</span><span style="color: black;">晚期胃癌传统的治疗<span style="color: black;">办法</span>有手术、放疗和化疗，但<span style="color: black;">针对</span>晚期胃癌手术治愈率低，且放化疗疗效欠佳。</span><strong style="color: blue;"><span style="color: black;">一句话概括，中国胃癌治疗形势严峻！</span></strong><strong style="color: blue;">01</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">靶向药、免疫药为晚期胃癌带来曙光！</strong></p><span style="color: black;">随着靶向、免疫治疗的兴起，胃癌<span style="color: black;">出现</span>、发展分子机制<span style="color: black;">科研</span>的<span style="color: black;">持续</span>深入，胃癌的靶向治疗崭露头角。靶向药、免疫药较高的疗效和较低的副<span style="color: black;">功效</span>，为晚期胃癌的治疗带来了曙光。</span><span style="color: black;"><span style="color: black;">日前</span>针对胃癌的靶点<span style="color: black;">重点</span><span style="color: black;">包含</span>EGFR、HER-2、VEGF、VEGFR、mTOc-MET、HGF等。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;">随着越来越多抗癌药的<span style="color: black;">显现</span>，<span style="color: black;">经过</span><span style="color: black;">长时间</span>治疗<span style="color: black;">掌控</span>肿瘤<span style="color: black;">发展</span>，将不治之症变成“慢性病“已<span style="color: black;">作为</span>可能。</span><strong style="color: blue;">02</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">胃癌新药新技术临床招募进行中！</strong></p><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">迎战胃癌，“国产版雷莫芦单抗”金妥昔单抗整装待发！</p>
      </strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">我国药企针对雷莫芦单抗相同靶点人血管内皮生长因子受体2（VEGFR2/KDR）进行深入<span style="color: black;">科研</span>、攻坚克难，</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">研制出了“国产版雷莫芦单抗”（Me-Too<span style="color: black;">制品</span>）金妥昔单抗，为胃癌<span style="color: black;">病人</span><span style="color: black;">存活</span>助力！</span></strong></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，金妥昔单抗在国内的Ⅰb/Ⅱ期临床<span style="color: black;">科研</span><span style="color: black;">已然</span>展开，计划招募76例晚期胃及胃食管结合部腺癌<span style="color: black;">病人</span>，挑战二线治疗<span style="color: black;">方法</span>！<strong style="color: blue;"><span style="color: black;">详细</span>纳入标准请咨询<span style="color: black;">没</span>癌家园医学部400-626-9916。</strong></span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率73%，晚期胃癌新<span style="color: black;">期盼</span>！CAR-T疗法CT041惊艳世界</p>
      </strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">9月16~21日召开的欧洲肿瘤内科学会（ESMO）年会上，由科济药业<span style="color: black;">研发</span>的靶向Claudin18.2（CLDN18.2）自体CAR-T候选<span style="color: black;">制品</span>CT041展现了其在消化系统肿瘤中的<span style="color: black;">明显</span>疗效，可谓是大放异彩！</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Claudin18.2(CLDN18.2)是一种胃特异性膜蛋白，被认为是胃癌和其他癌症类型的潜在治疗靶点。基于此，中国<span style="color: black;">科研</span>人员<span style="color: black;">研发</span>了国际上首个针对 Claudin18.2的CAR-T细胞。</span></p><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：</span></strong><a style="color: black;"><strong style="color: blue;"><span style="color: black;">国产实体瘤CAR-T疗法迎来新<span style="color: black;">发展</span>！剑指胃癌，CT041过关斩将进入确认性Ⅱ期临床<span style="color: black;">实验</span>！</span></strong></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">除了CT041<span style="color: black;">日前</span>正在开展临床<span style="color: black;">实验</span>外，<span style="color: black;">另一</span>一款针对既往接受过胃全切除术/胃大部切除术后的复发或转移性晚期胃腺癌（<span style="color: black;">包含</span>胃食管结合部腺癌）的</span><span style="color: black;"><strong style="color: blue;">靶向Claudin18.2 的CAR-T细胞制剂</strong></span><span style="color: black;">，名为</span><span style="color: black;"><strong style="color: blue;">LCAR-C18S</strong></span><span style="color: black;"><span style="color: black;">亦</span>在临床招募中。</span></span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">勇争靶点“高地”，新药Zolbetuximab使超半数<span style="color: black;">病人</span>受益！</p>
      </strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Zolbetuximab（IMAB362）是一类针对Claudin 18.2靶点的单克隆抗体<span style="color: black;">药品</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">在2016年ASCO大会上公开的数据中，采用Zolbetuximab+CAPOX化疗<span style="color: black;">方法</span>治疗局部晚期或转移性胃癌<span style="color: black;">病人</span>，</span><span style="color: black;"><strong style="color: blue;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为7.9个月，中位总<span style="color: black;">存活</span>期13.2个月；<span style="color: black;">显著</span>长于仅采用CAPOX化疗<span style="color: black;">方法</span>的4.8个月和8.4个月。</strong></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">在2019年公开的Ⅱ期<span style="color: black;">科研</span>数据中<span style="color: black;">亦</span>证实</span><span style="color: black;"><strong style="color: blue;">，Zolbetuximab治疗晚期胃癌或胃食管交界处癌或食道腺癌<span style="color: black;">病人</span>，临床获益率达到23%。</strong></span></span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>，Zolbetuximab<span style="color: black;">已然</span><span style="color: black;">得到</span>FDA的<span style="color: black;">准许</span>进行Ⅲ期临床<span style="color: black;">实验</span>，有望尽快得到更有价值的大型疗效数据。近期，Zolbetuximab治疗局部晚期不可切除或转移性胃及胃食管交界处腺癌<span style="color: black;">病人</span>的临床<span style="color: black;">实验</span><span style="color: black;">得到</span>国家<span style="color: black;">药物</span>监督管理局<span style="color: black;">准许</span>，正式<span style="color: black;">起始</span>在中国招募<span style="color: black;">病人</span>。<strong style="color: blue;">若癌友们想要<span style="color: black;">认识</span><span style="color: black;">详细</span>的入组标准请联系<span style="color: black;">没</span>癌家园医学部（400-626-9916）。</strong></span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">博主</span>有话说</strong></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">最后，<span style="color: black;">没</span>癌家园<span style="color: black;">博主</span>要告诫各位癌友不要<span style="color: black;">错失</span>任何治疗的机会，以延长<span style="color: black;">存活</span>期。</span><span style="color: black;"><span style="color: black;">因为</span>肺癌、肝癌、胃癌等癌种的病因<span style="color: black;">尤其</span><span style="color: black;">繁杂</span>，为进一步<span style="color: black;">提高</span><span style="color: black;">以上</span>难治性癌症的治疗效果，<span style="color: black;">必须</span>以“组合拳”，即采用靶向治疗、免疫治疗、质子治疗等。<span style="color: black;">另外</span>，在<span style="color: black;">怎样</span><span style="color: black;">选取</span>最佳治疗<span style="color: black;">方法</span>和用药上应该求助于国内外权威专家，<span style="color: black;">这般</span><span style="color: black;">才可</span>让广大癌友们少走弯路，得到最大的临床获益。</span><span style="color: black;"><strong style="color: blue;">本文为<span style="color: black;">没</span>癌家园原创，转载需授权</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">参考文献</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">https://www.sciencedirect.com/science/article/pii/S2667005422000047</span></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园提醒<span style="color: black;">病人</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">国内细胞免疫治疗技术，<span style="color: black;">包含</span><span style="color: black;">CAR-T细胞（除上市的三款CAR-T外）、树突细胞疫苗、NK细胞、TILs细胞、TCR-T细胞治疗、癌症疫苗等</span>
            </span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">技术均<span style="color: black;">处在</span>临床<span style="color: black;">实验</span><span style="color: black;">周期</span>，未获准在医院正式<span style="color: black;">运用</span>。国内<span style="color: black;">病人</span><span style="color: black;">能够</span>参加正规临床<span style="color: black;">实验</span>，在<span style="color: black;">大夫</span>的监管下<span style="color: black;">运用</span>，<span style="color: black;">没</span>癌家园网不<span style="color: black;">举荐</span><span style="color: black;">病人</span>冒然尝试任何医疗<span style="color: black;">公司</span>和<span style="color: black;">开发</span><span style="color: black;">公司</span>的收费治疗。</strong></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">热门<span style="color: black;">举荐</span></strong></span><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a><span style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">Welcome to join us！</strong></span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">扫码关注<span style="color: black;">没</span>癌家园</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">我帮你抗癌，你关注我到<span style="color: black;">恢复</span>~</p><strong style="color: blue;">点点分享</strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">点点赞</strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">点点在看</strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">

cvh132 发表于 2024-8-25 22:52:37

谷歌网站排名优化 http://www.fok120.com/

情迷布拉格 发表于 2024-9-10 18:07:30

论坛的成果是显著的，但我们不能因为成绩而沾沾自喜。

7wu1wm0 发表于 2024-9-27 05:25:06

请问、你好、求解、谁知道等。

4zhvml8 发表于 2024-10-21 20:53:44

谷歌外贸网站优化技术。

7wu1wm0 发表于 2024-10-26 19:24:04

你的话语如春风拂面，让我心生暖意。

4lqedz 发表于 2024-10-28 11:26:21

你的言辞如同繁星闪烁，点亮了我心中的夜空。

j8typz 发表于 2024-11-13 05:24:02

这篇文章真的让我受益匪浅，外链发布感谢分享！

m5k1umn 发表于 前天 12:42

你的见解真是独到，让我受益匪浅。

查看完整版本: 中国最新癌症报告出炉！肺癌、肝癌、胃癌成三大难治癌症，有哪些新药新疗法值得关注！